Three-year follow-up of a novel aqueous humor microshunt

Batlle J.F., Fantes F., Riss I., Pinchuk L., Alburquerque R., Kato Y.P., Arrieta E., Peralta A.C., Palmberg P., Parrish R.K., II, Weber B.A., Parel J.-M.

2016
Journal of Glaucoma

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Centro Laser, Santo Domingo, Dominican Republic; Ophthalmic Biophysics Center Bascom Palmer Eye Institute, University of MiamiMiller School of Medicine, United States; Anne Bates Leach Eye Hospital, University of Miami, United States; InnFocus Inc., Miami, FL, United States; Pôle Ophtalmologique de la Clinique Mutualiste, Pessac, Cedex, France

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications